Incyte Chairman and CEO Hervé Hoppenot is keynote speaker at the 187th Annual Dinner of the Delaware State Chamber of Commerce on Jan. 29.
Incyte, a biopharmaceutical company with roots in Califonia and Delaware established operations in 2002.
Since that time, Incyte has grown into a global organization with more than 2,400 employees and a portfolio of treatments in oncology and inflammation and autoimmunity,
Hoppenot joined Incyte in 2014 as CEO and was appointed Chairman of the Board in 2015. During Hoppenot’s tenure, Incyte revenue went from $511 million in 2014 to $3.4 billion in 2022. The company has tripled the number of clinical candidates in its portfolio, expanding beyond cancer to include research and development in inflammation and autoimmunity.
Incyte’s flagship drug Jakafi treats blood cancer. The company is building a drug pipeline with a cream for treating some skin conditions.
With global headquarters near Wilmington, Incyte has expanded and operations in North America, Europe, and Asia.
“I am honored to address Delaware’s vibrant and diverse business community at the Delaware State Chamber of Commerce’s 187th Annual Dinner,” said Hoppenot. “I look forward to sharing the Incyte story and how our innovative science is making an impact on the practice of medicine around the world.”
The Annual Dinner is the largest of the State Chamber’s annual events, more than 1,100 business leaders, dignitaries, and elected officials to the Chase Center on the Riverfront in Wilmington.
The evening’s program will include the presentation of the Josiah Marvel Cup award in honor of the memory of Josiah Marvel, who reorganized and was the first president of the modern-day State Chamber. The recipient of the Marvel Cup is kept secret until the night of the dinner.
Registration for the 187th Annual Dinner can be found online at https://web.dscc.com/events/187th-Annual-Dinner-3007/details.
